Rejuvenate Biomed finishes enrolling patients for trial of new drug treating muscle loss in COPD patients

Rejuvenate Biomed has completed recruitment in its randomized, double-blind, placebo-controlled Phase 2 MINT-COPD trial evaluating RJx-01 in older adults with COPD-induced muscle weakness and sarcopenia. The trial will assess safety and tolerability alongside measures of muscle strength, physical function and muscle fatigue resistance, and topline data are expected by year-end 2026, the company says. RJx-01 […] The post Rejuvenate Biomed finishes enrolling patients for trial of new drug treating muscle loss in COPD patients appeared first on Longevity.Technology.